Ann: PTX-200 AML Trial Progresses to Next Dose Level, page-15

I do hear you wasa. Back in March 2019 at the time of the last CR SYC stated the company was sustained for the next 18 months .. here we are pretty much exactly on schedule. Despite $7m COH I think the board have looked at risk mitigation here with this CR. If you were to fast forward 6 months with a possible failed Doherty trial behind us, no traction with Omni and PTX( our flagship) burbling along and taking an increasingly back seat, then throw in the mix a possible COVID global financial meltdown and we would be raising cash at way under 5.5c per share IMO. This CR does look premature I agree but best to move now than be on your knees in 6 months ... possibly. I suppose I’m more bullish around the CR because of my enter price, completely appreciate this is not he position of many though.